Tomocube, Inc. · KRX:475960
Tomocube — Investor Presentation (October 2024)
46 slides from Tomocube's investor presentation, Oct 15, 2024
Slide 1: Innovate the way we see life
Innovate the way we see life 4 F Tomocube
Slide 2: Disclaimer
Disclaimer BABE SARISS CHAO MAIEIE PresentationlM2| BH ASS SAOe FALS|AL EE (OlS} “SIAL” Ol] O16 APIEISSLICH. = reo] Yel “Ag HS Sel BAS AAA] SS SSSALICH Of B47} OFLI Ole] Ata} Bel AOR "L2H Sto Sto] S9 SELES ee AMPS |O|S-T, HAYORS ‘oe’, Mey, el’, ‘Ich’, (E)’ Sate Hols Resch. 91 “OSU IS BYE Hs} Sol Wie
Slide 3: Table of contents
Table of contents Prologue Chapter 1. Why Holotomography(HT) Chapter 2. Expanding the applications of HT Chapter 3. Investment Highlights Appendix
Slide 4: Prologue Tomocube, Inc.
Prologue Tomocube, Inc. 14 HpO|2 sted Ly MEAT MHEYCHS! Ast 3D 4B, MAIS Also] SAHel SBI] Sey NEW Market 27} 01S ‘ Ona 3D SBet, Msolst i, Nai (Organoids)- 8 a (Cell Therapies) aE f HLO|® AGIOIIAY 3D AL ZEA] S2}St 3p Feel 5 (Q7HRO|E, MIEAEH| S)S B/S PAPE TS BAP ss ; BRslo| HB}, Sule, ABSAOE AS 7hsét AC
Slide 5: Prologue
Prologue BRED Tayo|9| Bea Tomocube, Inc. 1 5 ce 3htel HHA] 0/018 7133S Soh BE bpO|o/o|=e ate12] Unmet Needs o44 JIE BA — neSy _| = ae "Nearaa) AS B7t USE| AE AL ee en “E |? Sal CH 7b Be 1 : AE . nga aa es SB GMOs oly ME AA BS Set HBA] 0/0/28 SS SS ME AM, HS Slo] MX SAAS Sag! MISE TESA] H[FEX| 244 7
Slide 6: Prologue Tomocube, Inc.
Prologue Tomocube, Inc. 16 ME BAO| MBS 7S EF SREDTAHN] ++ MEE SMO] Ze WHYS AAS: SSES WHS St 718 BE Fel SE cr Hr (Computed tomography) (Holotomography) X-ray aa 2410/74, LED Ate BAS AZ, ZA X-ray 4 joi) cH] aus BE] Baz DMD Clokst 29] XM Bars SoH 21a] 3D 25 AHS Cheret 2}2| 2D SE HS FAH MIZE 3D 72 MS &
Slide 7: Prologue
Prologue Tomocube, Inc. 17 Et HO] 2/2) Ate et) ee ce MALS] SEO] SEED THD] 71S HS Sse Als vy HLO|S Ate4o] DHRC HALA AM]! AY ALTO] BA Hfo|2 At SOfO| HPC HS] M7 ol] SEH A 7A St ve ory MoE oa BL tre tat century ox eS BaAlor Os »~ 4 ZEISS 2c AEH] we 21 iy SMASH, Sxtzlet century eames century ~ LR pts ASA
Slide 8: Label-free 3D Live Cell Imaging
Label-free 3D tive Cell tmagiaggs E Tomocube Cellular Responses and Recovery from High Levataf Reditive Oxygen Species (ROS) * Cell line: Hep3B * Microscope: HT-X1 * Observation duration: 4.5 hr * Time interval: 20 sec Bet ¢ : * Chip: ibidi p-Slide | Luer oy. + Flow rate: 0.23 pL/min 20 um
Slide 9: Unveiling the unseen: 3D Organoid visualization
gizewicus (i p 27eoje EF Tomocube Unveiling the unseen: 3D Organoid visualization Cell division #(116/361) 00:57:30
Slide 10: Why Holotomography (HT)
Why Holotomography (HT) 01. Benefits from HT 02. HT Platform (1) Hardware (2) Software (3) AI 03. 경쟁사 대비 압도적 비교 우위 (1) 홀로토모그래피 비교 (2) 세포 분석 기술 비교 04. 대외적으로 입증된 HT 기술력
Slide 11: Benefits from HT
Chapter 1. Why Holotomography(HT) Tomocube, Inc. 111 01. Benefits from HT + DHEAIOI HALA Beda Shr] SO} shes + HWS SW APR 7HSISIOL SA ALES Holotomography Platform J = _ Ut donlt 34481 WE OfD! A seas HIJA 4 zie] 3 ALI HT Sat 4 St HT 0/2 hel I AH (Lock-In 21) BULA MBIA (758 491 a) Biomarker ta MBIA (28
Slide 12: HT Platform (1) Hardware
Chapter 1. Why Holotomography(HT) Tomocube, Inc. |12 02. HT Platform (1) Hardware SALE H]FEA| O[0[2! 7[S JME ME SA BA EES AAI Needs SISPY otay wHaloy deeaea wd Glo] 21 AtEHo] A att 3D APB nie 24), o7}colc &) 2 HS 2D HIE #449] ard AUe Sue agg ulloe me (<150 um) £218 4 fl pa MEL AN7|BHIEA| H[EX|@ Bt T
Slide 13: HT Platform (2) Software
Chapter 1. Why Holotomography(HT) Tomocube, Inc. |13 02. HT Platform (2) Software ++ SWE Sel HT Salo] Bata GI ASS MAA 784 =a 1} ” Al 22 7/¥t ATE Soi FROR ME BA ATE SIO] 71S SEM stesof st} ~ 2022 ~ 2024 ~ TomoAnalysis 1.0 ~ TomoAnalysis 2.0 Pk It AEA BE Ht ~ 2017 ~ 2019 + AB 2Stt Mz ATA © 3D HT IOlEY
Slide 14: HT Platform (3) AI
Chapter 1. Why Holotomography(HT) Tomocube, Inc. 114 02. HT Platform (3) Al oo MAL S128 B S]a) S25 Al TIEEHT St BAIS! Biomarker #2 + Al HE GOES BIS + WE HT SAS ALA] SCS} AIJIEtLHT Sa 38 7 71S HT SSE M/S} A7| Ft ARS PS 1S ALOSHT StS, ONE, el Se Ache ler HTS Azel clots 3a}el etatol as et eat resolutio
Slide 15: Holotomography comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. | 15 03. SBA} HH] Set bat SS] (1) SBE STAD] bl ce BO AHO| UE 2 See Tayo] Sap SERED AHD| 7/5 eICtel Ste} Key Player » » 1 AICH 2aICH Future ze THAT (AINA) 1AMICHHT (ESE) 2AICH HT (EH) Future HT (ES 9H) a 3D Explorer HT-2H HT-X1 HT-X1 Max (25.1H AI OFS!
Slide 16: Cell analysis technology comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. 116 03. SBAt Che] SLA bat PS] (2) ME A 71S He oo ED AH NES elal/MS/7/5 DE Pola See Aa Az ete wate ts AE BH MIE ZA W7} BHI 24 ABOR MY 2AICH HT = 5 . at onlay BeE4 MECH Ta Tomocube (#4) e e e e 0 C e HT (2AiCH) ea 0 ala aa aan ie) ro) fe) ee O (e) O A P
Slide 17: Externally validated HT technology
Chapter 1. Why Holotomography(HT) Tomocube, Inc. 117 04. Hi2i4or BSE HT WSS > HEA] Be TehO| 72 A + HT Se Se BF 7s aa + BETH] HT + HT ALE Sat Jet + MAST 71g St a + IA AA! SAI oI + MREM|E BA 7a Ste The Alo] 71 7H sas 24 71 et + MLS MIAH HT lee aie at e e e e e 2005 2010 2015: ES AH Ao} 2017 : HT-2H BA
Slide 18: Expanding the applications of HT
Expanding the applications of HT 01. 토모큐브의 목표 시장 02. 확장성 (1) 오가노이드 확장성 (2) IVF(체외수정) 확장성 (3) 세포치료제 확장성 (4) 신약개발 확장성 (5) 비바이오 산업용
Slide 19: Target markets
Chapter 2. Expanding the applications of HT Tomocube, Inc. 119 01. ER AHO SF Ae ++ 3D M4, MMolst Alzo] AAS SmAHO| zt 713] ob, EOFS SEANt To 202714 SF 1202 21 + a BEX OOS NS BEE IVF(AL49) AS BEE MEAS AS BES HCS AS S97} 9 ee HES ola 49219] 418 SEBS 2071 $16 AUEXLZA| At TPSO|A| MEO] 3} 31 slop eweal An
Slide 20: Organoids
Chapter 2. Expanding the applications of HT Tomocube, Inc. |20 02. SH (1) S7HCOlE (gate! oe] 271) ce ACH HfO|S Arey Li Hal AAy O7po|S Ce Se UHol 4 troleraicr Q7HeO1E O18 cH AB! BEE Top 15 AFA 2S O7HLO|S NSH BH S HSAol MZ} L7H. 0|ES] fo “ bhole tet Uf Q7H OLE BS SOF a a3 one = 58 B71 Hal ao tt peverl
Slide 21: Organoids: pharma collaborations
Chapter 2. Expanding the applications of HT Tomocube, Inc. 121 02. Stat (1) O7FLoj& ce Q7LO|S HH SEH AHA SS acl Roche GD + Organ-on-a-Chip 71&3 o|Set SSA CHA OP MELAS! AI [ 2022 ) + Hans Clevers S21 + Institute for Human Biology (IHB) 34] 42!, 2l2t O7rOjES 0|Sst fe a7 gl et SE CD) - eractetnes oizt
Slide 22: Organoids: research institutions
Chapter 2. Expanding the applications of HT Tomocube, Inc. |22 02. Stat (1) O7FLoj& oe BEE QSOS BY BESO] MEA Ast Say C}eF$t Global Top Pharma} #4 BEe “nO 7S Ss AS 21S > Al 7[EE SSSR THD OF LO|S HE HAS SA 3D H|HEA| 0/0/22} AIS O|S3t Q7/LO|E BM BE DEES AIA] fa [2 Ba ‘BHM. J. Leeetal., Experimental & M
Slide 23: IVF
Chapter 2. Expanding the applications of HT Tomocube, Inc. 123 02. S124 (2) IVF asia) ce Sate H|HA| HT St SBat Al SAS Sol AAS ASSO] SS HOPS N |Z H]2|+-282| Unmet Needs + A TPS HEA SOLZt ALS HS FHA S18 BI SAI Zt 7H) 29] tle ew 71e 24 A me Flo oo ~ TH o: n iS] rot a IE IVF At: SAlOF SIO] HT= SUF OA Sa
Slide 24: Cell therapy
Chapter 2. Expanding the applications of HT Tomocube, Inc. 124 02. S183 (3) MIZEALEAl ce MEAEA| Mt St BAe] SAlA2| Unmet Needsol] cist HAlAel SEM AS HT J|Ht 241 SW 713 Soll MEA|ZAS| HAGA SA! ABS 91St 71S Het MEAEA] HAt SAO] SH S17/A Sat pum HT-based 24 SW |B Als ~~~ 0 a ym wa) B7ME/AEA SA aad 3D HIER
Slide 25: Drug discovery
Chapter 2. Expanding the applications of HT Tomocube, Inc. 125 02. 233 (4) Hope ce PDD(HHS 7[tt Ao SHEA Sta) ol] SEES eH 71548 ODS =u] BI AL Jigs MOE PDD Alo] Alot et IS SICH TDD Target-Based Drug Discovery C> Got O° Kh Knowndrug _—-Target-based Lead Lead Preclinical Clinical target assay identifica
Slide 26: Non-bio industrial: hybrid bonding
Chapter 2. Expanding the applications of HT Tomocube, Inc. |26 02. 22a (5) HIMPOle HAS ee HT 7|aS 28st Hybrid Bonding S #t=4l Advanced Packaging HAt Al@ Ze 0/1] 3D At (Hybrid Bonding 5) ‘PO|TY Ly OM] PAS Vole BUotA| S8otoj, Bet MAIS 712] SH StS el IE AL sont 3D FE Dee Se 7S | 307 THLE SH 7S (~1sec)
Slide 27: Non-bio industrial: glass substrate TGV
Chapter 2. Expanding the applications of HT Tomocube, Inc. 127 02. 22a (5) HIMPOle HAS ee HT 71SS 284t Glass Substrate (LEA Fe|7|Bt) BAL Alzt AIS wo Through Glass Via(TGV) 4|i}2] 34}2! 244} TGV 84 F Hz] SOS THe BAe BA SS IE BA » Sane Bite Sot TGV SAE Tz] 20) Taps) BAO ye nm I 3D 0101 SB iY oil} il i
Slide 28: Non-bio industrial: HT-R1 commercialization
Chapter 2. Expanding the applications of HT Tomocube, Inc. |28 02. S44 (5) HIH}O|O sted ce MAA 7|S7HSS Set steal, CASA] AAA 7B7HS St MAE BA 5 Net Atel AZ Bote Alles HT-R1 (Alpha) Gi AlABt 24\4 72 HT-R1 (Alpha) rev.3 7H et ¥ 24\43Q Aberration correction wel3 42 ¥ 2544 AIZS} & Hybrid Bonding 43 24 B7t
Slide 29: Non-bio industrial: peer group
Chapter 2. Expanding the applications of HT Tomocube, Inc. 129 02. S14 (5) HIH}O|S ee HIH}O|2 Zt A|Z2I peer group ae Bane *& Ol} KAt [54 OAF ojAeted Cat Su PAR Bu NAP Su AE Su OAF A7so4! 1,0029821 (NASDAQ) octal rise 389ee (NASDAQ) 14%2,1954H 4,551421 1,79642 1,606%2! Apo. LHS mh (23A 8.24824 3.2482
Slide 30: Investment Highlights
Investment Highlights 01. 토모큐브의 성공 비결 02. 기술성을 검증 받은 토모큐브 03. 상업성을 검증 받은 토모큐브 04. 글로벌 시장 확장 전략 05. 전방산업 확대에 대비한 선제적 투자 06. 바이오 소부장 국산화 선도 기업 07. 실적 가이던스
Slide 31: Key to Tomocube's success
Chapter 3. Investment Highlights Tomocube, Inc. 131 01. FRAY aS 4/28 ++ Sol SEM MSS Sel Set who] o Algol First Player Mii] SA 2H BSED AHO] 7s Hes ra eG HT SSaN8 a EH Player BES MHA SHS ASE AS 63.5% +30715 20234 +B 4S Sa Rese +514 PMA CHE] 7leaat O10} BI 3 FES SH 71a 2 7/4 & Major VCE At FA] +4404 ED
Slide 32: Technology validated
Chapter 3. Investment Highlights Tomocube, Inc. 132 02. 7138S 83 HE EBAY o oe BEB AMA ASE SED TeHMI9| S444 #=H 7le ate SB SRCE SRAY eS 25; El SEED THD AM ISS Lord EA Aoll AS AH cael Toiaononant — ( -SaarcHalir (mjelexiz) ) eo: Peer Group Nature Nature Nature Nature Methods Photonics Cell Biology Met
Slide 33: Commercially validated
Chapter 3. Investment Highlights Tomocube, Inc. 133 03. 4S 1S we SoA ee HTE Mal Sa12| 71S alg 2 oY ol rH 2 oH |o Hu [i] ms: E] ke > rad a eS 17H ORE [Bt TIHAP St FASAOe ABopD WE OH Dto|ze}e! BHTGIE +A sa as deta = HT SoH as 175 75 91 38 =-5 2019 2020 «2021 «= 2022-2 2023 2024.1H HOH 12H Bt Alt aH Sa
Slide 34: Global market expansion strategy
Chapter 3. Investment Highlights Tomocube, Inc. 134 04. BEY Alzt Shs met =o a ++ BEY ALO A] Choyet 7S Stet > BS Bersjol Azts ost aI9I a49| Se HE Stas s =O BES ane Stet t+] QIX|E ZSHS olst Sei/opae! Tomocube Europe Gevases FE AIA(S2) 2S “& eee Tomocube APAC ICUDE APIA, BRS, E47], WRC, S2HO1, MUIEA, A
Slide 35: Preemptive investment for downstream growth
Chapter 3. Investment Highlights Tomocube, Inc. | 35 OS. Hessted SHcHol] CHAISE 1A] = At + HHOLe + HlbfO]o Ate 42 S7} CHS Bl APS AIS] tw Sgt CAPA SE H}O|2 ABS F18t CAPA S1cH 300CH BEA AZe018 ABS Set S| SB9| Bel SH ¥ 70CH 2024(E) 2025(E) 2: HT-X! Ee) AB A 1
Slide 36: Localization of bio research equipment
바이오 연구장비 국산화 세포분석장비와 같은 정부 지원 정책 확대 고부가제품의 국산화율은 5% 미만 8,072 1,420 1,711 700 438 2015 2017 2018 2021 2024~
Slide 37: Performance guidance
Chapter 3. Investment Highlights Tomocube, Inc. 137 07. #4 7p0|H1~ ce BREED 10 HS SS SASS SoH 20264 FE] WA Holete = ABS, MAS AS ste © Ae HSH / Seo] Ho] B (eis: et 22) aa oso i seo 2024.3Q sy ono 50% 3! ine 8,589 5,800 3,747 EXC 1,871 Cs 1,645 (6,180) (Grose) 2022 2023 2024(E) 2025(E) 2026(E) 2027(E)
Slide 38: Appendix
Appendix 01. IPO Plan 02. 요약 재무제표 03. 회사 개요 04. 성장 연혁 05. Man Power (1) CEO (2) 주요 임원진 06. 이사회 구성
Slide 39: IPO Plan
Appendix Tomocube, Inc. |39 01. IPO Plan Ba72 SES sets SURES BRRAS 2,000,000 28.28% AYBEEBIAL SPO Bx01z7 10,9008 ~ 13,4008! stop jolgtAe 0.47% 4.94% y eyez 5002 aon A OE AL 15.71% Senora 21,800 “et 2! ~ 26,800 wet 2! 12,731,1942 ,731, oes AlHSOH 138,770 “42! 2! ~ 170,598 “Het 2 itd ~~ 47.35% ret 3.2
Slide 40: Summary financial statements
Appendix Tomocube, Inc. |40 02. 29F APA o TA SENSE che]: gh 2 BoA cle] sae al Fe 2021 2022 2023 Fe 2021 2022 2023 2024.1H SARE 27,700 22,126 15,952 11,895 | 1,625 1,871 3,747 2,928 uGSaRt 2,263 2,930 3,823 4,004 o onset 959 928 1,565 1,258 ASA, 29,963 25,055 19,775 15,899 oH SOleY 666 943 2,182 1,67
Slide 41: Company overview
Appendix Tomocube, Inc. 141 03. S|APHR AS AZ Slang @anFe CHEEOAt ShSa, S718 (24xb CHE) sua 2015. 08.24 Aza 5,336 wake age 678 (SANTA ABS IE) Fae BEES THT] 7[et AE SAY 71S Bt Ba] BARA CHMA $d Ald 155, 4 Suol www.tomocube.com ae HS KAIST — KAIST SEO Al AID FES] SLES AHN 7|\B 201514 4B AB BS 71a Best D
Slide 42: Growth history
Appendix Tomocube, Inc. 142 04. 42 a3 o 2015 - 2017 2018 - 2020 2021 - 2024 ~ 1MICH HT 433} 3 AHS LE Oo) EI $25} Ol Fle! T SESS St A Het JI AF AL ale! 2MICH HT SSS} St HpOlS Ate Alas Tey 2015 2017 2019 2021 2023 + DAs ag + IRS2SSaa se + 3¥[BZ83| PRISM AWARD Finalist + BAwAI [es AeeAE + UBAlS 7IBHHT
Slide 43: Man Power (1) CEO
Appendix Tomocube, Inc. 143 05. Man Power (1) CEO ee HOLS AP SOF ME eI} FA AE] Septal S22 ogo S7| A cezout BEAT], Hole O|0|8, ALSS SoSES AE APA ae Baw, Harvard-MIT 918t3} Ese] OS Bes] & Sx] BSS), 484812! (Fellow) oS Seetelel, Uetslel + ©, SI apsh7ig Beales, tatcHate! aE ‘SPIE Photonics West QPI #13]
Slide 44: Man Power (2) Key executives
Appendix Tomocube, Inc. 144 05. Man Power (2) #8 2! ce EHH SOF 1014 Of ato] HEat BSA BY Hetolet EME ares {2 ¥fAb, Univ. Cincinnati, BioMEMS. 22] + W,MOIESIA, CTO &CSO +H, OMA, toizicratulaiy, Eat yp + A SSMS Be, 277/81 +B S8S712, Holes + A, Boston Univ., A721 HES wees S}2] SAL, KAIST, M7iaateet Ze]
Slide 45: Board composition
Appendix Tomocube, Inc. |45 HESS ojstorzt, ceo HEAFO! solo}, ‘S}2{_ #tA}, Harvard-MIT Health Science and Technology ‘S}2{ —_ HIAb, Stanford University Be] + U,SERY, BsaeCEO > ae + A maNwAdE = SLKAIST, ait + 4, Park Scientific Instrument, Founder & CEO BSR vo1014, S718 swiot, ceo za =}2{— J.D., Seton
Slide 46: Tomocube
4 F Tomocube